These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 7956274)

  • 21. BN 52021: a platelet activating factor antagonist for preventing post-transplant renal failure. A double-blind, randomized study. The BN 52021 Study Group in Renal Transplantation.
    Grino JM
    Ann Intern Med; 1994 Sep; 121(5):345-7. PubMed ID: 8042824
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial.
    Giamarellos-Bourboulis EJ; Mylona V; Antonopoulou A; Tsangaris I; Koutelidakis I; Marioli A; Raftogiannis M; Kopterides P; Lymberopoulou K; Mouktaroudi M; Papageorgiou C; Papaziogas B; Georgopoulou AP; Tsaganos T; Papadomichelakis E; Gogos C; Ladas M; Savva A; Pelekanou A; Baziaka F; Koutoukas P; Kanni T; Spyridaki A; Maniatis N; Pelekanos N; Kotsaki A; Vaki I; Douzinas EE; Koratzanis G; Armaganidis A
    J Antimicrob Chemother; 2014 Apr; 69(4):1111-8. PubMed ID: 24292991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
    Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
    Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group.
    Knaus WA; Harrell FE; LaBrecque JF; Wagner DP; Pribble JP; Draper EA; Fisher CJ; Soll L
    Crit Care Med; 1996 Jan; 24(1):46-56. PubMed ID: 8565538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: a prospective, multi-center, double-blind, randomized phase II trial.
    Froon AM; Greve JW; Buurman WA; van der Linden CJ; Langemeijer HJ; Ulrich C; Bourgeois M
    Shock; 1996 May; 5(5):313-9. PubMed ID: 9156785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.
    Abraham E; Reinhart K; Svoboda P; Seibert A; Olthoff D; Dal Nogare A; Postier R; Hempelmann G; Butler T; Martin E; Zwingelstein C; Percell S; Shu V; Leighton A; Creasey AA
    Crit Care Med; 2001 Nov; 29(11):2081-9. PubMed ID: 11700399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter evaluation of a human monoclonal antibody to Enterobacteriaceae common antigen in patients with Gram-negative sepsis.
    Albertson TE; Panacek EA; MacArthur RD; Johnson SB; Benjamin E; Matuschak GM; Zaloga G; Maki D; Silverstein J; Tobias JK; Haenftling K; Black G; Cowens JW;
    Crit Care Med; 2003 Feb; 31(2):419-27. PubMed ID: 12576946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of a platelet activating factor antagonist (BN 52021) on neurologic outcome and histopathology in a canine model of complete cerebral ischemia.
    Hofer RE; Christopherson TJ; Scheithauer BW; Milde JH; Lanier WL
    Anesthesiology; 1993 Aug; 79(2):347-53. PubMed ID: 8342844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.
    Fisher CJ; Dhainaut JF; Opal SM; Pribble JP; Balk RA; Slotman GJ; Iberti TJ; Rackow EC; Shapiro MJ; Greenman RL
    JAMA; 1994 Jun; 271(23):1836-43. PubMed ID: 8196140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. The Ginkgolide Study Group in multiple sclerosis.
    Brochet B; Guinot P; Orgogozo JM; Confavreux C; Rumbach L; Lavergne V
    J Neurol Neurosurg Psychiatry; 1995 Mar; 58(3):360-2. PubMed ID: 7897422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
    Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
    N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.
    Panacek EA; Marshall JC; Albertson TE; Johnson DH; Johnson S; MacArthur RD; Miller M; Barchuk WT; Fischkoff S; Kaul M; Teoh L; Van Meter L; Daum L; Lemeshow S; Hicklin G; Doig C;
    Crit Care Med; 2004 Nov; 32(11):2173-82. PubMed ID: 15640628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis.
    Johnson CD; Kingsnorth AN; Imrie CW; McMahon MJ; Neoptolemos JP; McKay C; Toh SK; Skaife P; Leeder PC; Wilson P; Larvin M; Curtis LD
    Gut; 2001 Jan; 48(1):62-9. PubMed ID: 11115824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double blind, placebo controlled study of a platelet activating factor antagonist in patients with rheumatoid arthritis.
    Hilliquin P; Chermat-Izard V; Menkes CJ
    J Rheumatol; 1998 Aug; 25(8):1502-7. PubMed ID: 9712091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators.
    Angus DC; Birmingham MC; Balk RA; Scannon PJ; Collins D; Kruse JA; Graham DR; Dedhia HV; Homann S; MacIntyre N
    JAMA; 2000 Apr; 283(13):1723-30. PubMed ID: 10755499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis.
    Rice TW; Wheeler AP; Bernard GR; Vincent JL; Angus DC; Aikawa N; Demeyer I; Sainati S; Amlot N; Cao C; Ii M; Matsuda H; Mouri K; Cohen J
    Crit Care Med; 2010 Aug; 38(8):1685-94. PubMed ID: 20562702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis.
    Root RK; Lodato RF; Patrick W; Cade JF; Fotheringham N; Milwee S; Vincent JL; Torres A; Rello J; Nelson S;
    Crit Care Med; 2003 Feb; 31(2):367-73. PubMed ID: 12576938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.
    Shakoory B; Carcillo JA; Chatham WW; Amdur RL; Zhao H; Dinarello CA; Cron RQ; Opal SM
    Crit Care Med; 2016 Feb; 44(2):275-81. PubMed ID: 26584195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of PAF antagonist BN 52021 (Ginkolide B) on post-ischemic graft function in clinical lung transplantation.
    Wittwer T; Grote M; Oppelt P; Franke U; Schaefers HJ; Wahlers T
    J Heart Lung Transplant; 2001 Mar; 20(3):358-63. PubMed ID: 11257563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results.
    Dhainaut JF; Laterre PF; LaRosa SP; Levy H; Garber GE; Heiselman D; Kinasewitz GT; Light RB; Morris P; Schein R; Sollet JP; Bates BM; Utterback BG; Maki D
    Crit Care Med; 2003 Sep; 31(9):2291-301. PubMed ID: 14501959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.